四川医学2018，Vol.39Issue(4)：368-374,7.DOI:10.16252/j.cnki.issn1004-0501-2018.04.002
DPP-4抑制剂联合二甲双胍治疗2型糖尿病的胃肠道安全性评价
Evaluation of Gastrointestinal Tract Safety of DPP-4 inhibitor Combined with Metformin in the Treatment of Type 2 Diabetes
摘要
Abstract
Objective To systematic evaluate the gastrointestinal tract safety of DPP-4 inhibitors combined with metformin in the treatment of type 2 diabetes,and provide evidence and advice for the treatment of diabetes.Methods Randomized controlled trials of DPP-4 inhibitor combined with metformin in the treatment of type 2 diabetes were performed using databases PubMed,The Cochrane Library and EM-base(OVID).Data of gastrointestinal adverse events were extracted and analyzed by using Revman5.2 software and fixed effect model to compare the difference of gastrointestinal adverse events between DPP-4 inhibitor combined metformin and metformin alone in treatment of type 2 diabetes.Results A total of 26 RCT and 1 1454 patients with type 2 diabetes were included in the study.Compared with metformin alone,sitagliptin(metformin dose more than 1500mg/d)and vildagliptin respectively combined with metformin can significantly reduce the occurrence of abdominal pain(0.53 OR,95％ CI:0.35 ～0.81,P =0.003;OR 0.21,95％ CI:0.06 ～0.73,P =0.01).In other types of gastrointestinal adverse reactions(diarrhea,nausea,vomiting,etc.),still can not believe that compared with metformin alone,sitagliptin,vildagliptin,saxagliptin,linagliptin and alogliptin combined with metformin respectively have the advantage (P all more than 0.05).Conclusion Compared with metformin alone,sitagliptin and vildagliptin combined with metformin had more advantages in reducing the incidence of abdominal pain.关键词
DPP-4抑制剂/二甲双胍/2型糖尿病/胃肠道不良反应/系统评价Key words
DPP-4 inhibitor/metformin/type 2 diabetes/gastrointestinal adverse events/meta-analysis分类
医药卫生引用本文复制引用
杜素雅,吴行伟,童荣生,龙恩武,何霞..DPP-4抑制剂联合二甲双胍治疗2型糖尿病的胃肠道安全性评价[J].四川医学,2018,39(4):368-374,7.基金项目
四川省科技厅科技基础条件平台建设基金资助项目(编号:14010159) （编号:14010159）
